PE20060561A1 - Compuestos derivados de hidantoina - Google Patents
Compuestos derivados de hidantoinaInfo
- Publication number
- PE20060561A1 PE20060561A1 PE2005000812A PE2005000812A PE20060561A1 PE 20060561 A1 PE20060561 A1 PE 20060561A1 PE 2005000812 A PE2005000812 A PE 2005000812A PE 2005000812 A PE2005000812 A PE 2005000812A PE 20060561 A1 PE20060561 A1 PE 20060561A1
- Authority
- PE
- Peru
- Prior art keywords
- absent
- hydantoin
- arilo
- halogen
- derived compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58850204P | 2004-07-16 | 2004-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20060561A1 true PE20060561A1 (es) | 2006-07-13 |
Family
ID=35134266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005000812A PE20060561A1 (es) | 2004-07-16 | 2005-07-14 | Compuestos derivados de hidantoina |
Country Status (21)
Country | Link |
---|---|
US (2) | US7482370B2 (de) |
EP (1) | EP1778676B1 (de) |
JP (1) | JP4943327B2 (de) |
KR (1) | KR20070032787A (de) |
CN (1) | CN101018782A (de) |
AR (1) | AR050169A1 (de) |
AT (1) | ATE478864T1 (de) |
AU (1) | AU2005275213A1 (de) |
BR (1) | BRPI0513433A (de) |
CA (1) | CA2573764A1 (de) |
DE (1) | DE602005023172D1 (de) |
EC (1) | ECSP077163A (de) |
ES (1) | ES2349041T3 (de) |
IL (1) | IL180736A0 (de) |
MX (1) | MX2007000668A (de) |
NO (1) | NO20070893L (de) |
PE (1) | PE20060561A1 (de) |
RU (1) | RU2007105685A (de) |
TW (1) | TWI297269B (de) |
WO (1) | WO2006019768A1 (de) |
ZA (1) | ZA200700384B (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7504424B2 (en) * | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
AR050169A1 (es) | 2004-07-16 | 2006-10-04 | Schering Corp | Compuesto para el tratamiento de trastornos inflamatorios |
US7488745B2 (en) * | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
CN101282962A (zh) * | 2005-08-12 | 2008-10-08 | 先灵公司 | 用于治疗炎性疾病的化合物 |
AR059037A1 (es) | 2006-01-17 | 2008-03-12 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
CA2649543A1 (en) * | 2006-04-21 | 2007-11-01 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
CA2661605A1 (en) | 2006-08-31 | 2008-03-06 | Schering Corporation | Hydantoin derivatives useful as antibacterial agents |
DE102007038957A1 (de) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-Thioxo-pyridazinderivate |
WO2009038784A1 (en) * | 2007-09-21 | 2009-03-26 | Amgen Inc. | Triazole fused heteroaryl compounds as p38 kinase inhibitors |
EP2346857B1 (de) * | 2008-09-24 | 2019-11-27 | Merck Sharp & Dohme Corp. | Verbindungen zur behandlung von entzündungserkrankungen |
EP2331528B1 (de) | 2008-09-24 | 2020-05-27 | Merck Sharp & Dohme Corp. | Verbindungen zur behandlung von entzündungserkrankungen |
EP2355825A2 (de) | 2008-11-10 | 2011-08-17 | Schering Corporation | Verbindungen zur behandlung entzündlicher erkrankungen |
US8541572B2 (en) | 2008-11-10 | 2013-09-24 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory disorders |
SI2536706T1 (sl) * | 2010-02-11 | 2017-10-30 | Celgene Corporation | Derivati arilmetoksi izoindolina in sestavki,ki jih vsebujejo ter metode uporabe le-teh |
EP2597084B1 (de) | 2010-07-08 | 2016-06-29 | Kaken Pharmaceutical Co., Ltd. | N-hydroxyformamidderivat und arzneimittel damit |
US20150232455A1 (en) * | 2010-12-15 | 2015-08-20 | Allan C. Krueger | Anti-viral compounds |
JP6091427B2 (ja) * | 2011-12-09 | 2017-03-08 | 科研製薬株式会社 | ピリドン誘導体およびそれを含有する医薬 |
WO2013129622A1 (ja) | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
PT2925757T (pt) | 2012-11-19 | 2018-01-09 | Novartis Ag | Compostos e composições para o tratamento de doenças parasitárias |
JP6211530B2 (ja) * | 2012-11-19 | 2017-10-11 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
US9593106B2 (en) | 2013-02-07 | 2017-03-14 | Heptares Therapeutics Limited | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists |
TWI636782B (zh) | 2013-06-07 | 2018-10-01 | 科研製藥股份有限公司 | (+)-5-(3,4-二氟苯基)-5-[(3-甲基-2-氧代吡啶-1(2h)-基)甲基]咪唑啶-2,4-二酮及含有此之醫藥 |
EP3087069B1 (de) | 2013-12-23 | 2019-01-30 | Norgine B.V. | Als ccr9-modulatoren verwendbare verbindungen |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
EP4086249A3 (de) | 2015-09-02 | 2023-02-15 | Trevena, Inc. | 6-gliedrige heterozyklen mit delta-opioidrezeptor-modulierenden verbindungen, verfahren zur herstellung und verwendung davon |
JP6987792B2 (ja) * | 2016-05-27 | 2022-01-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Rock阻害剤としてのトリアゾロンおよびテトラゾロン |
CN108069942A (zh) * | 2016-11-10 | 2018-05-25 | 四川大学 | 苯酞吡唑酮类偶联物、其制备方法和用途 |
AU2018221705B2 (en) | 2017-02-17 | 2022-10-27 | Trevena, Inc. | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
CA3052480A1 (en) | 2017-02-17 | 2018-08-23 | Trevena, Inc. | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
EP3762379A1 (de) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identifizierung und verwendung von erk5-inhibitoren |
EP3917935A4 (de) * | 2019-01-30 | 2022-11-16 | Avista Pharma Solutions, Inc. | Synthetischer prozess und neuartige zwischenprodukte |
AU2020381485A1 (en) * | 2019-11-14 | 2022-06-16 | Foresee Pharmaceuticals Co., Ltd. | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4110536A (en) * | 1977-04-18 | 1978-08-29 | Miles Laboratories, Inc. | Derivatives of 5-(indol-3-yl)hydantoin |
CA2083891A1 (en) * | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Heterocyclic compounds, compositions containing them and their use in therapy |
US6228869B1 (en) | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
WO1998039303A1 (en) * | 1997-03-03 | 1998-09-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
JP2003507362A (ja) | 1999-08-18 | 2003-02-25 | ワーナー−ランバート・カンパニー | マトリックスメタロプロテイナーゼ阻害剤として有用なヒドロキサム酸化合物 |
WO2001070734A2 (en) | 2000-03-17 | 2001-09-27 | Bristol-Myers Squibb Pharma Company | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
CA2440632A1 (en) | 2001-03-15 | 2002-09-26 | Astrazeneca Ab | Metalloproteinase inhibitors |
CA2447475A1 (en) | 2001-05-25 | 2002-12-05 | Chu-Biao Xue | Hydantion derivatives as inhibitors of matrix metalloproteinases |
AU2002346729A1 (en) | 2001-12-20 | 2003-07-09 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases |
US7294624B2 (en) | 2001-12-20 | 2007-11-13 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
AU2003261319A1 (en) | 2002-08-01 | 2004-02-23 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
GB0221250D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
AU2003282920A1 (en) | 2002-10-04 | 2004-05-04 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
WO2004056766A1 (en) | 2002-12-19 | 2004-07-08 | Vertex Pharmaceuticals Incorporated | Inhibitors of tace |
US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
AR050169A1 (es) | 2004-07-16 | 2006-10-04 | Schering Corp | Compuesto para el tratamiento de trastornos inflamatorios |
US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
AR059037A1 (es) | 2006-01-17 | 2008-03-12 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
CA2661605A1 (en) | 2006-08-31 | 2008-03-06 | Schering Corporation | Hydantoin derivatives useful as antibacterial agents |
-
2005
- 2005-07-13 AR ARP050102901A patent/AR050169A1/es not_active Application Discontinuation
- 2005-07-13 BR BRPI0513433-1A patent/BRPI0513433A/pt not_active IP Right Cessation
- 2005-07-13 WO PCT/US2005/024771 patent/WO2006019768A1/en active Application Filing
- 2005-07-13 MX MX2007000668A patent/MX2007000668A/es active IP Right Grant
- 2005-07-13 DE DE602005023172T patent/DE602005023172D1/de active Active
- 2005-07-13 RU RU2007105685/04A patent/RU2007105685A/ru not_active Application Discontinuation
- 2005-07-13 AU AU2005275213A patent/AU2005275213A1/en not_active Abandoned
- 2005-07-13 CN CNA2005800304595A patent/CN101018782A/zh active Pending
- 2005-07-13 ES ES05771446T patent/ES2349041T3/es active Active
- 2005-07-13 US US11/180,863 patent/US7482370B2/en active Active
- 2005-07-13 JP JP2007521589A patent/JP4943327B2/ja not_active Expired - Fee Related
- 2005-07-13 EP EP05771446A patent/EP1778676B1/de active Active
- 2005-07-13 AT AT05771446T patent/ATE478864T1/de not_active IP Right Cessation
- 2005-07-13 KR KR1020077001084A patent/KR20070032787A/ko not_active Application Discontinuation
- 2005-07-13 CA CA002573764A patent/CA2573764A1/en not_active Abandoned
- 2005-07-14 PE PE2005000812A patent/PE20060561A1/es not_active Application Discontinuation
- 2005-07-14 TW TW094123832A patent/TWI297269B/zh not_active IP Right Cessation
-
2007
- 2007-01-12 ZA ZA200700384A patent/ZA200700384B/xx unknown
- 2007-01-12 EC EC2007007163A patent/ECSP077163A/es unknown
- 2007-01-16 IL IL180736A patent/IL180736A0/en unknown
- 2007-02-16 NO NO20070893A patent/NO20070893L/no not_active Application Discontinuation
-
2008
- 2008-12-18 US US12/338,353 patent/US7683085B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BRPI0513433A (pt) | 2008-05-06 |
CN101018782A (zh) | 2007-08-15 |
US7482370B2 (en) | 2009-01-27 |
MX2007000668A (es) | 2007-03-08 |
IL180736A0 (en) | 2007-06-03 |
ATE478864T1 (de) | 2010-09-15 |
ZA200700384B (en) | 2008-09-25 |
WO2006019768A1 (en) | 2006-02-23 |
US7683085B2 (en) | 2010-03-23 |
TW200616620A (en) | 2006-06-01 |
KR20070032787A (ko) | 2007-03-22 |
ES2349041T3 (es) | 2010-12-22 |
JP4943327B2 (ja) | 2012-05-30 |
AR050169A1 (es) | 2006-10-04 |
US20060205797A1 (en) | 2006-09-14 |
JP2008506692A (ja) | 2008-03-06 |
US20090111803A1 (en) | 2009-04-30 |
RU2007105685A (ru) | 2008-08-27 |
AU2005275213A1 (en) | 2006-02-23 |
DE602005023172D1 (de) | 2010-10-07 |
TWI297269B (en) | 2008-06-01 |
ECSP077163A (es) | 2007-02-28 |
NO20070893L (no) | 2007-04-13 |
EP1778676A1 (de) | 2007-05-02 |
CA2573764A1 (en) | 2006-02-23 |
EP1778676B1 (de) | 2010-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20060561A1 (es) | Compuestos derivados de hidantoina | |
PE20071241A1 (es) | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios | |
UY29530A1 (es) | Compuestos quimicos | |
GT200500242A (es) | Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
ECSP055705A (es) | (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2 | |
PE20070852A1 (es) | Compuestos derivados de hidantoina como inhibidores de la enzima de conversion del factor alfa de necrosis tumoral (tace) | |
ECSP078062A (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
GT200300096A (es) | Activadores de cicloalquil sustituidos y cicloalquil oxigenados de glucoquinasa | |
BRPI0507968A (pt) | oxidação de compostos orgánicos a ph alto | |
PE20081256A1 (es) | Triazalopiridacina como modulador de la actividad proteina cinasa | |
ECSP056072A (es) | Pirimidinonas sustituidas | |
DE602005026962D1 (de) | Arylcarboxamide und ihre verwendung als antitumormittel | |
PE20080842A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
CY1112754T1 (el) | Μεθοδοι και ενδιαμεσα για την παρασκευη παραγωγων ν4-φαινυλ-κιναζολιν-4-αμινης | |
UY26694A1 (es) | Activadores de fenil glucocinasa para - arilo o hetero sustituidos | |
PA8571001A1 (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
UY27224A1 (es) | Inhibidores de la rho-quinasa | |
GT200500286A (es) | Analogos de anilino-pirimidina | |
EA200700702A1 (ru) | Аналоги локсапина и способы их применения | |
CY1108275T1 (el) | Χημικες ενωσεις | |
BR0312037A (pt) | Oxidação de compostos orgânicos | |
PE20070505A1 (es) | Inhibidores de glutamato de metaloproteinasas de matriz y agrecanasas | |
PA8610601A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
UY29458A1 (es) | Heterociclos sustituidos y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |